JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB180187

Anti-LAG-3 antibody [EPR4392(2)] - C-terminal

4

(2 Reviews)

|

(20 Publications)

Rabbit Recombinant Monoclonal LAG-3 antibody. C-terminal. Suitable for IHC-P and reacts with Human samples. Cited in 20 publications.

View Alternative Names

CD223, FDC, LAG3, Lymphocyte activation gene 3 protein, LAG-3

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LAG-3 antibody [EPR4392(2)] - C-terminal (AB180187)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LAG-3 antibody [EPR4392(2)] - C-terminal (AB180187)

Immunohistochemical analysis of paraffin embedded Human tonsil tissue labeling LAG-3 with ab180187 at 1/1000.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LAG-3 antibody [EPR4392(2)] - C-terminal (AB180187)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LAG-3 antibody [EPR4392(2)] - C-terminal (AB180187)

Immunohistochemical analysis of paraffin embedded Human Hodgkins lymphoma tissue labeling LAG-3 with ab180187 at 1/1000.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-LAG-3 antibody [EPR4392(2)]

  • Carrier free

    Anti-LAG-3 antibody [EPR4392(2)] - BSA and Azide free

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-LAG-3 antibody [EPR4392(2)] - C-terminal

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-LAG-3 antibody [EPR4392(2)] – C–terminal

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-LAG-3 antibody [EPR4392(2)] – C–terminal

  • 660 APC

    APC Anti-LAG-3 antibody [EPR4392(2)] – C–terminal

  • 578 PE

    PE Anti-LAG-3 antibody [EPR4392(2)] – C–terminal

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-LAG-3 antibody [EPR4392(2)] - C-terminal

  • Carrier free

    Anti-LAG-3 antibody [EPR4392(2)] - Low endotoxin, Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR4392(2)

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/1000", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

LAG-3 also known as CD223 is a transmembrane protein with a mass of approximately 70 kDa. It acts as a checkpoint molecule similar to CTLA-4 and PD-1 in the immune system. LAG-3 is expressed on activated T cells natural killer cells and some dendritic cells. It interacts with its ligand MHC class II leading to inhibition of cellular proliferation and cytokine secretion an important part of immune response regulation.
Biological function summary

LAG-3 is involved in maintaining immune homeostasis and preventing autoimmunity. It is not part of a complex but works in synergy with other immune checkpoint molecules. When interacting with MHC class II LAG-3 transmits inhibitory signals that attenuate immune cell responses. Its role in immune regulation helps to balance immune activation and tolerance which is essential for preventing tissue damage while protecting against pathogens.

Pathways

The inhibitory role of LAG-3 integrates into the T cell receptor (TCR) signaling pathway and is also linked to the PD-1 signaling pathway. In TCR signaling LAG-3 negatively regulates T cell activation. LAG-3 is functionally related to proteins like PD-1 and CTLA-4 sharing similar roles in immune checkpoint pathways that are critical for maintaining immune balance.

LAG-3 has links to cancer and autoimmune diseases. In cancer LAG-3 expression on tumor-infiltrating lymphocytes correlates with immune evasion by tumors. This relationship appears in various cancers including melanoma and renal cell carcinoma. In autoimmune diseases LAG-3's expression on regulatory T cells helps control conditions such as multiple sclerosis. It collaborates with CTLA-4 in modulating immune responses that prevent excessive immune activation and tissue damage associated with autoimmunity.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Lymphocyte activation gene 3 protein. Inhibitory receptor on antigen activated T-cells (PubMed : 20421648, PubMed : 35761082, PubMed : 7805750, PubMed : 8647185). Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells (PubMed : 30580966, PubMed : 32920841, PubMed : 35761082, PubMed : 39671469, PubMed : 7589152, PubMed : 8647185, PubMed : 9159144). Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation (PubMed : 40101708). Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation (PubMed : 40101708, PubMed : 40592325). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed : 20421648, PubMed : 7805750, PubMed : 8647185). Also mediates immune tolerance : constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).. The LAG3-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 35981087, PubMed : 40101708). The blockage of the LAG3- and PDCD1-mediated pathways results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 35981087, PubMed : 40101708).. Secreted lymphocyte activation gene 3 protein. May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
See full target information LAG3

Publications (20)

Recent publications for all applications. Explore the full list and refine your search

Cancer immunology, immunotherapy : CII 74:215 PubMed40411616

2025

LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Yuxuan Zhang,Zijing Zhou,Yuanyuan Rui,Fanhao Kong,Zhoubo Guo,Gang Zhao,Jun Wang,Jiacheng Li,Fangdong Zhao,Hui Huang,Fang Fang,Jiarui Zhang,Tian Zhang,Wencheng Zhang,Ping Wang,Xi Chen,Peng Zhen,Qingsong Pang

Cancers 16: PubMed39766109

2025

Microenvironmental Traits of Classical Hodgkin's Lymphoma in Adolescents and Their Prognostic Impact.

Applications

Unspecified application

Species

Unspecified reactive species

Clara Bertuzzi,Simona Righi,Giovanna Motta,Maura Rossi,Matteo Carella,Giulia Gabrielli,Elena Facchini,Maurizio Baldassarre,Arcangelo Prete,Pier Luigi Zinzani,Massimo Mascolo,Claudio Agostinelli,Elena Sabattini

Frontiers in immunology 15:1302761 PubMed38390332

2024

Immune checkpoint ligands expressed on mature high endothelial venules predict poor prognosis of NSCLC: have a relationship with CD8 T lymphocytes infiltration.

Applications

Unspecified application

Species

Unspecified reactive species

Jing Luo,Xiuhuan Shi,Yumeng Liu,Jian Wang,Hao Wang,Xuena Yang,Qian Sun,Zhenzhen Hui,Feng Wei,Xiubao Ren,Hua Zhao

Nature medicine 29:2814-2824 PubMed37857711

2023

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Applications

Unspecified application

Species

Unspecified reactive species

Jason J Luke,Manish R Patel,George R Blumenschein,Erika Hamilton,Bartosz Chmielowski,Susanna V Ulahannan,Roisin M Connolly,Cesar A Santa-Maria,Jie Wang,Shakeela W Bahadur,Andrew Weickhardt,Adam S Asch,Girish Mallesara,Philip Clingan,Monika Dlugosz-Danecka,Monika Tomaszewska-Kiecana,Halyna Pylypenko,Nada Hamad,Hedy L Kindler,Bradley J Sumrow,Patrick Kaminker,Francine Z Chen,Xiaoyu Zhang,Kalpana Shah,Douglas H Smith,Anushka De Costa,Jonathan Li,Hua Li,Jichao Sun,Paul A Moore

Clinical cancer research : an official journal of the American Association for Cancer Research 29:4268-4277 PubMed37566222

2023

Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.

Applications

Unspecified application

Species

Unspecified reactive species

Bahar Saberzadeh-Ardestani,Rondell P Graham,Sara McMahon,Eze Ahanonu,Qian Shi,Crystal Williams,Antony Hubbard,Wenjun Zhang,Andrea Muranyi,Dongyao Yan,Zhaohui Jin,Kandavel Shanmugam,Frank A Sinicrope

Journal of ovarian research 16:93 PubMed37179337

2023

Lymphocyte-activation gene 3 protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Sumika Zaitsu,Mitsutake Yano,Sawako Adachi,Maiko Miwa,Tomomi Katoh,Yasushi Kawano,Masanori Yasuda

Frontiers in immunology 13:934078 PubMed36172351

2022

Single-cell transcriptome analysis reveals T-cell exhaustion in denosumab-treated giant cell tumor of bone.

Applications

Unspecified application

Species

Unspecified reactive species

Meiling Yang,Fen Wang,Guohao Lu,Mingzhe Cheng,Wei Zhao,Changye Zou

iScience 25:104926 PubMed35992303

2022

Host and microbiome features of secondary infections in lethal covid-19.

Applications

Unspecified application

Species

Unspecified reactive species

Martin Zacharias,Karl Kashofer,Philipp Wurm,Peter Regitnig,Moritz Schütte,Margit Neger,Sandra Ehmann,Leigh M Marsh,Grazyna Kwapiszewska,Martina Loibner,Anna Birnhuber,Eva Leitner,Andrea Thüringer,Elke Winter,Stefan Sauer,Marion J Pollheimer,Fotini R Vagena,Carolin Lackner,Barbara Jelusic,Lesley Ogilvie,Marija Durdevic,Bernd Timmermann,Hans Lehrach,Kurt Zatloukal,Gregor Gorkiewicz

Cancer cell international 22:46 PubMed35093085

2022

Correction to: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Fan Luo,Jiaxin Cao,Feiteng Lu,Kangmei Zeng,Wenjuan Ma,Yan Huang,Li Zhang,Hongyun Zhao

Frontiers in immunology 12:778329 PubMed34975867

2021

Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.

Applications

Unspecified application

Species

Unspecified reactive species

Carlo Sorrentino,Luigi D'Antonio,Cristiano Fieni,Stefania Livia Ciummo,Emma Di Carlo
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com